Big splash this morning from CatalYm GmbH as news of its oversubscribed $150M Series D financing is gaining broad attention throughout the biotech space. Canaan is proud to have co-led this round alongside Bioqube Ventures. The CatalYm team will leverage these news funds to expand its clinical development of #visugromab, starting with new randomized Phase 2b studies in select checkpoint naive frontline and second-line treatment settings. Congrats to Canaan's own Colleen Feriod Cuffaro who sits on the CatalYm board of directors. Read more details in the press release here: https://lnkd.in/dBfHK4sU
Canaan
Venture Capital and Private Equity Principals
San Francisco, California 18,357 followers
We’re an early-stage VC firm that invests in entrepreneurs with visionary ideas.
About us
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With a diversified fund and over 200 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 33 years. Canaan’s focus areas include Consumer Tech, Enterprise, Fintech, Frontier Tech and Life Sciences. To learn more about our people and our portfolio, please visit canaan.com.
- Website
-
http://www.canaan.com
External link for Canaan
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Partnership
- Founded
- 1987
- Specialties
- Fintech, Enterprise SaaS, Digital Health, Biopharma Products & Platform, Medtech & Tools, Big Data /Cloud, Consumer, SaaS Security, and Frontier Tech
Locations
-
Primary
Get directions
27 South Park
Suite 201
San Francisco, California 94107, US
-
Get directions
2765 Sand Hill Road
Menlo Park, CA 94025, US
-
Get directions
285 Riverside Avenue
Suite 250
Westport, CT 06880, US
-
Get directions
821 Broadway, 3rd Floor
Public Entrance at 51 East 12th
New York, NY 10003, US
Employees at Canaan
Updates
-
Canaan reposted this
Excited to announce Canaan's Series A investment in Nagish, partnering with Tomer Aharoni, Alon Ezer and team as they leverage AI to make accessibility a reality for millions!
AI for Human Connection: Enabling Equitable Communication with Nagish
Laura Chau on LinkedIn
-
Canaan reposted this
Did you know it's estimated training GPT-4 took 50 GWh of electricity - roughly equivalent to powering 5k homes for a year? Check out my colleagues Rayfe Gaspar-Asaoka's, Nandu Anilal's, and my musings on resulting implications for the AI stack below:
AI's shift to efficiency - Canaan
canaan.com
-
Big news from Pathios Therapeutics today as the company has appointed Paul G Higham as its new CEO. Paul brings more than 20 years of C-level executive biotechnology company experience to Pathios. Founding CEO, Stuart Hughes, has transitioned to CSO and will focus on the company’s first-of-its-kind GPR65 inhibition approach to #immuno-oncology. This strengthening of the company's leadership team aligns with Pathios' maturation as it prepares to enter clinical development with its first-in-class GPR65 antagonist by the end of 2024. Read more details in the press release here: https://lnkd.in/espnJXtD
Pathios Therapeutics Appoints Paul G. Higham as Chief Executive Officer as Company Prepares to Enter the Clinic - Pathios Therapeutics %
https://pathiostherapeutics.com
-
Canaan portfolio company ThirtyFiveBio has been awarded its second prestigious Biomedical Catalyst grant from Innovate UK in less than a year. This non-dilutive funding, which totals more than $815,000, will support the team's continued work on its innovative GPR35 inhibition approach to treating gastrointestinal disease and cancers. Importantly, the work funded by this grant will enable ThirtyFiveBio to create and validate a biomarker-driven process for precision patient selection for its planned clinical trials of its proprietary GPR35 inhibitors. Our Brent Ahrens sits on the ThirtyFiveBio board. Read more details in the press release here: https://lnkd.in/eMdviF45
ThirtyFiveBio Awarded Second Grant by Innovate UK for £643k - ThirtyFiveBio
https://30fivebio.com
-
Day One Biopharmaceuticals is back in the news. On the heels of its recent FDA approval for #Ojemda, the company has joined the antibody-drug conjugate arena through a licensing deal with MabCare Therapeutics. Day One plans to advance the new asset, MTX-13, into the clinic in the coming months. We look forward to following its development. Canaan's Julie Grant is one of the company’s co-founders and a member of its board of directors. #cancer #ADC https://lnkd.in/gg_jwggu
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers | Day One Biopharmaceuticals, Inc.
ir.dayonebio.com
-
Canaan reposted this
Thrilled to announce that Canaan has led the Series A at Aim Security. Incredibly excited to partner with Matan Getz and Adir G. They are solving the highest business potential security challenge in the industry today. Great to work with Yoav Leitersdorf, Ofer Schreiber, and Justin Somaini at YL Ventures.
Harnessing the power of Generative AI, securely at scale, with AIM
Joydeep Bhattacharyya on LinkedIn
-
More good news from the Canaan healthcare portfolio with Antiva Biosciences, Inc. announcing formation of a top-tier Scientific and Development Advisory Board. These thought leaders will provide great insight and guidance for the company as it continues to advance development of ABI-2280 for #HPV infection and the #pre-cancerous lesions that the infection causes. Canaan's Wende Hutton sits on the board.
Antiva is delighted to announce the formation of our Scientific and Development Advisory Board which is comprised of distinguished scientists, clinicians and seasoned drug developers from world renowned academic institutions and industry. Their expertise will be invaluable as we work to develop ABI-2280 as the first approved drug treatment for HPV infection and pre-cancerous lesions caused by the infection. For more details, please follow the link below to read the press release which was issued earlier today. https://lnkd.in/gexijspP
Antiva Biosciences Announces Formation of Scientific and Development Advisory Board
antivabio.com
-
Congrats to the team at Grey Wolf Therapeutics for presenting the first clinical data on its lead #immuno-oncology candidate at the #ASCO 2024 annual meeting. Encouraging first results in patients as the company now moves into the study's combination treatment cohorts.
📣 🔬 📊 Disclosing our first clinical data! Our Chief Medical Officer Tom Lillie has been presenting at #ASCO, highlighting our first clinical data for our lead immuno-oncology candidate, GRWD5769. The initial data from our ongoing study are incredibly encouraging, with clear signs of target engagement provide compelling support for our antigen modulation strategy in immuno-oncology. A few key takeaways from the presentation: 👉 GRWD5769 was well tolerated, with predictable pharmacokinetics following repeat oral administration in all dose cohorts (up to 200 mg BID). 👉 Dose-dependent target engagement as evidenced by modulation of the immunopeptidome. 👉 Clinical proof-of-mechanism, confirming the expected mechanistic effects of ERAP1 inhibition and consistent with those seen in preclinical models. 👉 Initial, early efficacy assessments demonstrating stable disease achieved by a number of patients, some of whom have remained on treatment for nearly a year. The dose escalation portion of the trial continues, where we have recently initiated combination dosing with GRWD5769 and cemiplimab. With our recent Series B extension, we now have plans for further expansion cohorts in the near future. We are incredibly proud of the team and the rapid progress we have made to this point in development, to deliver our ERAP inhibitors to the patients who need them the most. Read more in the full data release here: https://lnkd.in/e54cJEXA #ASCO #immunotherapy #immunooncology #clinicaltrials #ERAP
Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting - Grey Wolf Therapeutics
https://greywolftherapeutics.com
-
Looking forward to today's fireside chat at #BIO featuring Canaan's own Nina Kjellson. She will sit down with Allison DeAngelis from STAT News to talk all things relevant to the VC biopharma world. Stop by if you are at BIO today - from 3:00 - 4:00 p.m. in Room 30 DE. https://lnkd.in/eUJKQ4e9
Fireside Chat with Nina Kjellson, General Partner, Canaan Partners
convention.bio.org